Herpesvírus bovino tipos 1, 2 e 5: sensibilidade a antivirais in vitro, patogenia e terapêutica experimental em coelhos

• Autor(a) principal: Dezengrini, Renata
• Data de Publicação: 2009
• Tipo de documento: Tese
• Idioma: por
• Título da fonte: Manancial - Repositório Digital da UFSM
• Texto Completo: http://repositorio.ufsm.br/handle/1/4039
• topic: Óxido nítrico; INOS; NNOS; BoHV-5; BoHV-1; Coelhos; Patogenia; Antiviral; Foscarnet; Ganciclovir; Aciclovir; Nitric oxide; Rabbits; Pathogenesis; Antiviral activity; Foscarnet; Gancyclovir; Acyclovir; CNPQ::CIENCIAS AGRARIAS::MEDICINA VETERINARIA

Aspects of bovine herpesvirus 5 (BoHV-5) pathogenesis and experimental therapies against BoHV-1 and BoHV-5 were investigated in vitro and in inoculated rabbits. In chapter 1, we investigated the role of nitric oxide (NO), a component of innate immunity against pathogens, in the neurological disease by BoHV-5 in rabbits. Spectrophotometry for NO products revealed that NO levels were significantly increased in several regions of the brain of rabbits with neurological disease [F(4, 40)=3.33; P<0.02]. Quantification of NO levels in the brain at different time points after virus inoculation revealed a gradual increase [F(12, 128)=2.82; P<0,003], correlated spatially and temporally with virus dissemination within the brain and preceding the development of neurological signs. Thus, we propose that the overproduction of NO in the brain of BoHV-5-infected rabbits may participate in the pathogenesis of neurological disease. In chapter 2, the activity of three anti-herpetic drugs was tested against BoHV-1, BoHV-2 and BoHV-5 in vitro by plaque reduction assay. Acyclovir was moderately active against the three viruses; Gancyclovir was moderately effective against BoHV-2, and to a lesser extent against BoHV-5, being poorly active against BoHV-1. Foscarnet (PFA) exhibited the most pronounced antiviral activity, being the only drug that, at the concentration of 100 ìg/mL, completely inhibited plaque formation by all three viruses. In chapter 3, we report the activity of PFA in rabbits inoculated with BoHV-1 or BoHV-5. Rabbits inoculated with BoHV-5 and treated with 100 mg/kg of PFA presented mortality rates (11/22 or 50%) statistically lower than non-treated controls (21/22 ou 95.4%) (P<0.0008). A significant reduction in the mean virus titers was observed at day 3 pi, the peak of virus shedding [F(9,108) = 2,23; P<0.03]. Reduction in virus shedding, frequency, severity and duration of ocular signs were also observed in rabbits inoculated with BoHV-1 into the conjunctival sac, comparing to the controls. The prolonged incubation period and the reduction in the duration of the clinical course of the PFA-treated group was significant (P<0.005 and P<0.04, respectively). Therefore, the activity of PFA in vivo against BoHV-1 and BoHV-5 may be exploited in further experimental therapies. In chapter 4, we investigated the effect of the inhibition of the inducible isoform of nitric oxide synthase (iNOS), associated or not with PFA treatment, on neurological infection by BoHV-5 in rabbits. Groups of BoHV-5-inoculated rabbits were treated with the iNOS inhibitor aminoguanidine (AG); with PFA; with both drugs; or maintained as virus controls. Morbidity and mortality rates were 100% (6/6) in the groups AG and CV, 66.7% (4/6) in the group PFA and 83.3% (5/6) in the group AG+PFA. The incubation period was significantly lower (P<0.05) and the onset of neurological disease occurred earlier and was more severe in the group AG. These results demonstrate that treatment with PFA reduced morbidity and mortality rates associated to BoHV-5 infection, that AG treatment anticipated the development of neurological signs, and that the development of neurolocial disease was delayed in the group treated with both drugs. Taken together, these results contribute to the knowledge of the pathogenesis of BoHV-5 neurological disease and pave the way for other experimental pathogenesis and therapy studies.